Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$38.05M |
$0.27
+6.38%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$37.93M |
$0.81
+8.10%
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$37.16M |
$4.97
+0.91%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$36.48M |
$13.89
-0.43%
|
|
BDMD
Baird Medical Investment Holdings Limited
BDMD is a medical device manufacturer focused on microwave ablation systems and related hardware, a core medical devices category.
|
$36.21M |
$1.44
+1.41%
|
|
JANL
Janel Corporation
Life Sciences activities include recombinant proteins and enzymes production (antibodies, reagents).
|
$36.18M |
$32.00
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$35.89M |
$1.55
+6.51%
|
|
POCI
Precision Optics Corporation, Inc.
The business includes design and manufacture of components/subassemblies for medical devices, i.e., Medical Device Components.
|
$35.80M |
$4.57
+1.78%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$35.77M |
$8.41
-1.75%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$35.77M |
$2.46
+3.14%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.70M |
$5.34
+1.71%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$35.48M |
$1.95
+1.56%
|
|
MURA
Mural Oncology plc
Company develops oncology-focused immunotherapies, including engineered cytokine therapies (nemvaleukin) and related assets.
|
$35.00M |
$2.02
-3.57%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$34.86M |
$0.71
+3.77%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$33.84M |
$0.95
-0.46%
|
|
VNRX
VolitionRx Limited
VolitionRx's Nu.Q platform enables liquid biopsy cancer diagnostics by detecting nucleosome/epigenetic biomarkers in blood.
|
$33.49M |
$0.31
+3.98%
|
|
HBIO
Harvard Bioscience, Inc.
HBIO generates recurring revenue from consumables used with its medical devices and bioproduction platforms (biochips, reagents, etc.).
|
$33.37M |
$0.75
+1.78%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$33.06M |
$2.23
+5.92%
|
|
RMTI
Rockwell Medical, Inc.
Rockwell Medical's core offerings are dialysis-related consumables (acid and bicarbonate concentrates, single-use bicarbonate cartridge, and at-home packs) used with dialysis equipment.
|
$33.02M |
$0.96
+4.81%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$32.71M |
$4.43
-0.36%
|
|
MYO
Myomo, Inc.
MyoPro is a prosthetic upper-limb device designed to replace or assist movement for partially paralyzed limbs, fitting Prosthetics & Implants.
|
$32.64M |
$0.87
+3.99%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$32.55M |
$0.07
|
|
FEMY
Femasys Inc.
Femasys manufactures medical devices and biometrics for women's reproductive health (FemBloc, FemaSeed, FemVue, etc.).
|
$32.27M |
$1.00
+0.44%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$31.52M |
$0.72
+1.27%
|
|
YI
111, Inc.
Private label medical devices and biometrics offerings under the healthcare product lineup.
|
$31.21M |
$3.65
+4.29%
|
|
PLUR
Pluri Inc.
PluriCDMO provides cell-therapy manufacturing services, generating revenue and serving as a core business line.
|
$31.07M |
$3.90
+4.28%
|
|
QDMI
QDM International Inc.
Health/medical insurance products are distributed via the company’s insurance brokerage activities.
|
$30.99M |
$18.36
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$30.63M |
$4.75
+1.71%
|
Showing page 30 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
